What is the difference between FEV1 change in percentage predicted value and change over baseline in the assessment of bronchodilator responsiveness in patients with COPD?

被引:5
作者
Jian, Wenhua [1 ]
Zheng, Jinping [1 ]
Hu, Yi [2 ]
Li, Yin [2 ]
Gao, Yi [1 ]
An, Jiaying [1 ]
机构
[1] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou Inst Resp Dis, Guangzhou 510120, Guangdong, Peoples R China
[2] Guangzhou Med Univ, Guangzhou 510182, Guangdong, Peoples R China
关键词
Airflow obstruction; bronchodilator responsiveness; chronic obstructive pulmonary disease (COPD); forced vital capacity (FVC); forced expiratory volume in one second (FEV1); OBSTRUCTIVE PULMONARY-DISEASE; SALMETEROL/FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE; COMBINATION; PREVENTION; SALMETEROL; HEALTH;
D O I
10.3978/j.issn.2072-1439.2013.08.14
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Several criteria are clinically applied in the assessment of significant bronchodilator responsiveness in chronic obstructive pulmonary disease (COPD). The present study aimed to investigate the differences in various degree of severity of COPD among these criteria. Methods: After 400 micrograms of salbutamol administered via spacer by metered dose inhaler (MDI), forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) changes (including percentage change, absolute change and absolute change in percentage predicted value) were retrospectively analysed in 933 stable patients with mild-to-very-severe COPD. Significant bronchodilator responsiveness was assessed using American Thoracic Society and European Respiratory Society (ATS-ERS) criterion based on FEV1 or/and FVC (both >= 12% increase over baseline and >= 200 mL) and FEV1 percentage predicted criterion (>= 10% absolute increase in percentage predicted FEV1) in different grades of COPD. Results: Of the patients [age 66.8 years, baseline FEV1 974 mL (39.3% predicted) and FVC 2,242 mL], mean improvements were 126 mL in FEV1 and 265 mL in FVC; 21.4% and 45.3% met ATS-ERS criterion based on FEV1 and FVC, respectively; and 13.5% met FEV1 percentage predicted criterion. The responsive ratios of ATS-ERS criterion based on FEV1 to FEV1 percentage predicted criterion in grade I, II, III and IV of COPD were 0.95:1.26:2.53:6.00, respectively (P<0.01 in grade II and P<0.001 in grade III). As the degree of severity increased, the mean improvement of FEV1 was reduced; on the contrary, that of FVC was increased. Conclusions: Compared with FEV1 percentage predicted criterion, ATS-ERS criterion based on FEV1 as well as FVC, the later in particular, detected a larger percentage of patients with significant responsiveness. The increasing difference was relevant as a function of the severity of airflow obstruction.
引用
收藏
页码:393 / 399
页数:7
相关论文
共 22 条
  • [1] Bronchodilator response in the lung health study over 11 yrs
    Anthonisen, NR
    Lindgren, PG
    Tashkin, DP
    Kanner, RE
    Scanlon, PD
    Connett, JE
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (01) : 45 - 51
  • [2] Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease
    Barnes, NC
    Qiu, YS
    Pavord, ID
    Parker, D
    Davis, PA
    Zhu, L
    Johnson, M
    Thomson, NC
    Jeffery, PK
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (07) : 736 - 743
  • [3] Global strategy for asthma management and prevention: GINA executive summary
    Bateman, E. D.
    Hurd, S. S.
    Barnes, P. J.
    Bousquet, J.
    Drazen, J. M.
    FitzGerald, M.
    Gibson, P.
    Ohta, K.
    O'Byrne, P.
    Pedersen, S. E.
    Pizzichini, E.
    Sullivan, S. D.
    Wenzel, S. E.
    Zar, H. J.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (01) : 143 - 178
  • [4] The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD
    Ben Saad, Helmi
    Prefaut, Christian
    Tabka, Zouhair
    Zbidi, Abdelkrim
    Hayot, Maurice
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2008, 21 (05) : 767 - 773
  • [5] INTERPRETATION OF BRONCHODILATOR RESPONSE IN PATIENTS WITH OBSTRUCTIVE AIRWAYS DISEASE
    BRAND, PLP
    QUANJER, PH
    POSTMA, DS
    KERSTJENS, HAM
    KOETER, GH
    DEKHUIJZEN, PNR
    SLUITER, HJ
    [J]. THORAX, 1992, 47 (06) : 429 - 436
  • [6] Buist AS, 2008, INT J TUBERC LUNG D, V12, P703
  • [7] Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    Calverley, Peter M. A.
    Anderson, Julie A.
    Celli, Bartolome
    Ferguson, Gary T.
    Jenkins, Christine
    Jones, Paul W.
    Yates, Julie C.
    Vestbo, Jorgen
    Calverley, P. M. A.
    Anderson, J. A.
    Celli, B.
    Ferguson, G. T.
    Jenkins, C.
    Jones, P. W.
    Knobil, K.
    Yates, J. C.
    Vestbo, J.
    Cherniack, R.
    Similowski, T.
    Cleland, J.
    Whitehead, A.
    Wise, R.
    McGarvey, L.
    John, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) : 775 - 789
  • [8] Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD
    Celli, Bartolome R.
    Tashkin, Donald P.
    Rennard, Stephen I.
    McElhattan, Jennifer
    Martin, Ubaldo J.
    [J]. RESPIRATORY MEDICINE, 2011, 105 (08) : 1176 - 1188
  • [9] Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
    Hanania, Nicola A.
    Sharafkhaneh, Amir
    Celli, Bartolome
    Decramer, Marc
    Lystig, Ted
    Kesten, Steven
    Tashkin, Donald
    [J]. RESPIRATORY RESEARCH, 2011, 12
  • [10] Post-bronchodilator spirometry reference values in adults and implications for disease management
    Johannessen, Ane
    Lehmann, Sverre
    Omenaas, Ernst R.
    Eide, Geir Egil
    Bakke, Per S.
    Gulsvik, Amund
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (12) : 1316 - 1325